Dysplasia Diagnostics Limited
Dysplasia Diagnostics Limited develops AI-driven, non-invasive liquid biopsy diagnostic solutions for early cancer detection, personalized treatment monitoring, and patient management. Their key products include DiNanoQ, an early cancer diagnostic test profiling platelet RNA for rare molecular events, and DiNanoTrack, a treatment monitoring platform detecting drug resistance. The company aims to expand global cancer screening with affordable, scalable methods deployable in low-income countries. They conduct clinical trials (CCANED-CIPHER) involving 6,000 participants to validate their AI-based blood test for multiple cancers. Their system outperforms DNA-based liquid biopsy methods, providing comprehensive patient insights via diagnostic and therapeutic dashboards, positioning them as innovators in cancer diagnostics and treatment management.
Dysplasia Diagnostics Limited
Dysplasia Diagnostics Limited develops AI-driven, non-invasive liquid biopsy diagnostic solutions for early cancer detection, personalized treatment monitoring, and patient management. Their key products include DiNanoQ, an early cancer diagnostic test profiling platelet RNA for rare molecular events, and DiNanoTrack, a treatment monitoring platform detecting drug resistance. The company aims to expand global cancer screening with affordable, scalable methods deployable in low-income countries. They conduct clinical trials (CCANED-CIPHER) involving 6,000 participants to validate their AI-based blood test for multiple cancers. Their system outperforms DNA-based liquid biopsy methods, providing comprehensive patient insights via diagnostic and therapeutic dashboards, positioning them as innovators in cancer diagnostics and treatment management.